Alloy Therapeutics and CDMO Wheeler Bio formed a nonexclusive, preferred service offering to advance potential new products from discovery to CMC development, GMP manufacturing, and clinical material supply for existing and future ATX-Gx platform users and Alloy Discovery Service partners who also contract Portable CMC™ development services with Wheeler Bio. Aligned with its open collaboration model, Alloy partners are still free to use any CDMO of their choice.

“Following every antibody and bispecific discovery process, CMC becomes the critical path to treating patients. We developed this preferred offering with Wheeler to support Alloy’s partners with the highest quality cell line development and GMP manufacturing process possible,” said Errik Anderson, CEO and founder at Alloy Therapeutics. “Alloy is helping to lower the cost of drug development by reducing our partners’ downstream payments dollar-for-dollar on their path to the clinic. Wheeler’s high-quality, predictable, fit-for-purpose approach increases the probability of success and reduces the time to clinic for these drug programs.”

Antibody discovery platforms

Alloy provides antibody discovery platforms and services with over 150 partners to date. The company’s ATX-Gx platform is a transgenic mouse strain for fully human antibody discovery.

“By closely aligning Alloy’s discovery platform with Wheeler’s development and manufacturing platform, our ecosystem clients benefit immensely by skipping the CDMO RFP process while reducing risk in tech transfers,” said Jesse McCool, CEO and co-founder at Wheeler. “Our bioprocess models are in lockstep with ATX-Gx derived antibodies.”

“We are elated to participate as an early adopter of the Alloy-Wheeler partnership to speed our path from discovery to CMC development and first patient dosing,” stated Hemanta Baruah, co-founder and CEO at Aakha Biologics. “Both Alloy and Wheeler are laser focused on meeting our needs as a small biotech startup with specific goals to generate early data to further enable our fundraising efforts.”

Previous articleUtilizing Proteomic Strategies to Uncover Novel Biomarkers and Mechanisms in Heart Failure
Next articleIn the Century of Biology: Bringing Great Science to Life